As oncologists, we face death on a daily basis. However, taking one's own life intentionally is an infrequent event. Experienced physicians usually remember those few occasions when their patients committed suicide.
Hematopoietic SCT (HSCT) is a highly intensive medical procedure, and is usually done with ambitious expectations on both the patient's and doctor's ends. Here, we present a case of suicide after a failure of HSCT.
AG, a business woman of Jewish descent, was born and had lived all her life in Argentina. Her past medical and psychiatric history was unremarkable. At the age of 55 years, she was diagnosed with CLL of T-cell origin. Her disease proved refractory to three lines of chemotherapy given in the first 6 months following diagnosis. She was then offered an allogeneic HSCT from her HLA-matched sister. The patient chose to continue her medical care in Israel. Upon arrival she was in respiratory distress due to lung leukostasis and pulmonary emboli. She had a huge spleen, diffuse lymphadenopathy and marked peripheral edema. These problems required immediate action that included leukopheresis and the insertion of a vena caval filter, after which her medical status stabilized. She then underwent the transplant procedure as planned. After 2 months, the spleen size gradually decreased, the lymphadenopathy disappeared, the peripheral edema became minimal and the patient was once again optimistic regarding her prognosis. Six months following the transplant, while she gradually regained her functional status and was discharged to ambulatory care, recurrence was noted with elevated lymphocyte count of recipient origin. At this point, we chose to offer the patient another aggressive chemotherapy course to be followed by donor lymphocyte infusion.
AG asked for a short vacation before any further treatment. She was discharged for a weekend vacation, and jumped out of the window of her rented apartment to her immediate death.
Several epidemiological studies across different countries and cultural backgrounds confirm that the rate of suicide is somewhat increased among cancer patients. A recent report based on the Surveillance, Epidemiology and End Results database found an age-sex-race-adjusted rate of 31.4/100 000 person years among cancer patients compared with 16.7/100 000 in the general population. Thus, in the United States suicide is twice as high among cancer patients as it is in the reference population. Risk factors include male gender, single (unmarried or divorced), patients with previous suicide attempts, any psychiatric illness and those with poor social networking support. 1 The first year after diagnosis and especially the first 3 months are associated with an increased risk. 2 A second smaller peak is between 12 and 14 months following diagnosis and is possibly the result of either disease progression or failure of treatment. 3 Suicide in the general population seems as an extreme manifestation of failure to cope with chronic distress, whereas in cancer patients, acute stressors that severely affect quality of life such as pain, physical impairment, depression, and loss of independence and autonomy are often the triggers for suicidal action. Suicide is therefore perceived by some as a more rational act in the context of cancer. 1 Depression is a common finding in the oncology population. The reported prevalence of major depression in cancer patients ranges from 3 to 38% depending on the diagnostic criteria used and on patient characteristics. Younger age, a prior history of depression, uncontrolled symptoms and the stage of the disease are all at increased risk. 4 Even when the most stringent criteria are used, major depression is diagnosed in 7% and minor depression in 11% of patients with advanced disease. Depression is associated with a desire to die. 5 Among 44 terminally ill patients, all 10 patients who desired death were found to be suffering from clinical depressive illness. 6 Depression is therefore the link between physical illness and the act of suicide.
DISCUSSION
The suicide of AG came as a complete surprise to all of us who took care of her. The long stay and the intensive medical care within a transplant unit makes patient-doctor bond particularly strong. We all had the impression that AG had a strong and stable personality. She could handle recurrent failure after various chemotherapy courses, critical life-threatening situations, the complications of the transplant procedure and living in a foreign country apart from her loved ones. Depression was never a part of her emotional repertoire. AG had undergone a complicated and highly risky procedure with an intent of cure. The options following an early relapse range from an aggressive, usually experimental, approach, through palliative disease control treatments with the main goal being the alleviation of symptoms, to providing only supportive care in a hospice or hospice-like environment. As an active transplant unit, we tend to focus on treatments with intent to cure, especially in a young patient, knowing that sometimes, as in this case, chances of success are scarce. We tend to forget that this approach is not the only option for patients facing death, and does not necessarily apply to everyone. Decisions regarding treatment at any point, but more specifically toward the end of life must be personally tailored to suit our patients.
In the case of AG, we failed to provide a protective environment. Perhaps, by introducing the option of palliative care in the face of so many previous treatment failures, we could have prevented her violent death.
In memory of Dr Roy Arad.
